The association between malignancy and thrombosis has been recognized for over a
century and a half. Patients with cancer have an elevated risk of both initial and recurrent …

Background Recent guidelines recommend consideration of the use of oral edoxaban or
rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However …

Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …

This consensus document is proposed to clinicians to provide the whole spectrum of deep
vein thrombosis management as an update to the 2017 consensus document. New data …

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary
embolism (PE), is a preventable cause of in-hospital death, and one of the most prevalent …

Cancer-associated thrombosis (CT) is associated with a high risk of recurrent venous
thromboembolic (VTE) events that require extended anticoagulation in patients with active …

Efficacy and safety of anticoagulant treatment for venous thromboembolism (VTE) may vary
in patients with different cancer sites. We evaluated the rates of VTE recurrence and major …

Background It is unclear if direct oral anticoagulant (DOAC) is efficacious and safe for
prophylaxis of venous thromboembolism (VTE) in ambulatory patients with cancer. Methods …

Importance It is unclear whether the clinical benefits associated with non–vitamin K
antagonist oral anticoagulants (NOACs) are similar to those associated with low-molecular …

Background The ever-growing complexity of cancer-associated thrombosis (CAT), with new
antineoplastic drugs and anticoagulants, distinctive characteristics, and decisions with low …